Pre-clinical studies of allogeneic stem cell transplantation suggest that depletion of naive T cells from donor lymphocytes will reduce the risk of GvHD but preserve immunity to infectious pathogens. In this study, we have established a clinical-grade protocol under good manufacturing practice conditions for purging CD62L + naive T cells from steady-state leukapheresis products using the CliniMACS system. The efficacy of immunomagnetic CD62L depletion was assessed by analysis of cell composition and functional immune responses. A median 2.9 log CD62L depletion was achieved with no evidence of CD62L shedding during the procedure and a mean T-cell yield of 47%. CD62L
INTRODUCTION
Several methods of allodepletion are being explored for their efficacy in reducing the risk of GvHD following allogeneic haematopoietic stem cell transplantation (allo-SCT).
1-2 Because alloreactivity is mainly derived from the naive T-cell population, 3 one approach for separating GvHD-inducing T cells from pathogen-specific T cells is to select memory T cells for adoptive transfer. Murine studies have shown that CD62L − T cells are able to engraft and respond to Ag challenge, but unlike the CD62L + T-cell population do not induce GvHD. 4 In addition to differences in T-cell repertoire, memory cells also possess repertoireindependent properties that limit their capacity to sustain effector cytokine synthesis and induce tissue injury. 5 Human CD62L
− memory T cells also demonstrate reduced responses to allogeneic Ag stimulation compared with CD62L + T cells but maintain reactivity to viral Ags. 6 These findings offer the opportunity of using memory T cells to enhance immune reconstitution following allo-SCT and provide broad immunity to multiple pathogens without the risk of GVHD. The feasibility of naive T-cell removal from donor leukaphereses using commercially available CD45RA reagents has also recently been reported, 7, 8 although how products lacking CD45RA + cells compare with those lacking CD62L + cells is not known. In this current study, we demonstrate for the first time the feasibility of clinical-grade immunomagnetic selection of CD62L − cells under good manufacturing practice (GMP) conditions and describe the composition and functions of the resulting product.
CD62L depletion and the retention of CD62L
− cells for clinical use, is a relatively simple platform that can be tested in early phase trials and offers the potential for implementation in most transplant centres.
MATERIALS AND METHODS
Cell preparation and immunomagnetic depletion Healthy volunteer peripheral blood mononuclear cell (PBMC) donors and allogeneic sibling leukapheresis donors provided written informed consent for their use in research as approved by the local ethics committee. The protocol developed for clinicalscale removal of CD62L + cells was performed under GMP conditions within a Grade B classified clean-room laboratory (Class 100, ISO 5) and batch manufacturing records were produced for each validation run. PBMCs were transferred into a 600 mL transfer bag (Fenwal, Lake Zurich, IL, USA) and washed in pre-chilled CliniMACS phosphate PBS-EDTA buffer (Miltenyi Biotec, Bergisch Gladbach, Germany) supplemented with 0.5% human serum albumin (Bio Products Laboratory, Elstree, UK) at 2000 rpm on the COBE 2991 cell processor (Terumo BCT, Lakewood, CO, USA) for 10 min and subsequently labelled with CliniMACS CD62L reagent (Miltenyi Biotec) for 30 min under gentle agitation at room temperature. Following incubation, cells were re-washed and re-suspended in a final vol of 80-100 mL in PBS-EDTA-0.5% human serum albumin. CD62L-labelled cells were depleted in a Grade B laboratory, using the 2.1 depletion programme on the CliniMACS plus instrument with a CliniMACS TS kit (both Miltenyi Biotec). Samples were taken pre-selection and following depletion for cell counts, immunophenotyping and sterility testing. For processing the steps performed in a Grade A microbiological safety cabinet, continuous particle counting was carried out using an ErgoTouch airborne particle counter (Merck, Darmstadt, Germany) measuring particles ⩾ 0.5 μm and ⩾ 5 μm in size. Environmental monitoring was performed during the process, by tryptone soya agar settle plates (Oxoid, Basingstoke, UK). Smallscale depletions were performed using anti-CD62L or anti-CD45RA beads using LD columns (all Miltenyi Biotec) according to the manufacturer's protocol.
Flow cytometric analysis
The following antibodies specific for human cell-surface Ags were used: CD3-Viogreen, CD8-PerCP, CD27-PE, CD62L-Vioblue (Miltenyi Biotec), CD4-APC-Cy7, CD45RA-FITC, CCR7-PE-Cy7 (BioLegend, San Diego, CA, USA), CD19-FITC, CD14-FITC, CD28-FITC, CD56-PE, FoxP3 AF488 and IFN-γ PE (BD Biosciences, Franklin Lakes, NJ, USA). Samples were run on a MACSQuant flow cytometer (Miltenyi Biotec) or a BDFortessa (BD Biosciences) and data were analysed using FlowJo v.7.6 (TreeStar, Ashland, OR, USA).
Functional assays IFN-γ-secreting cells were detected as previously described by enzyme-linked immunospot assay 9 or by intracellular staining. 10 Antiviral CD8 + T cells were detected using CMV HLA-A*02:01/ VLAELVKQI IE-1, HLA-A*02:01/NLVPMVATV pp65 and HLA-A*24:02/ QYDPVAALF pp65) and EBV (A*02:01/GLCTLVAML BMLF-1) pentamers (all ProImmune, Oxford, UK). HLA-mismatched MLR were performed as described previously. 2 Figure S3) .
RESULTS

Evaluation
Comparison of parallel CD45RA and CD62L depletions (n = 12) showed a significant increase in the proportion of CD8 + T cells within the CD62L-depleted fraction (58.4 ± 22.5%) compared with CD45RA-depleted fraction (16.9 ± 8.4%), indicating substantially greater retention of this population using the former method. This observation was reversed when analysing the proportion of CD4 + T cells (41.5 ± 22.5% vs 80.9 ± 8.4%) following depletion (Supplementary Figure S4a and b) . The alloreactivity of unmodified PBMC, CD62L
− and CD45RA − cells were compared in MLR using CFSE-labelled responders and HLA-mismatched allogeneic stimulators (n = 7). Alloreactivity in responding gated-CD8 + or -CD4
+ T cells was reduced in CD62L -cells (Supplementary Figure S4c and Figure S4e) . There was a trend for CD62L − fractions to retain greater frequencies of anti-CMV-specific T cells than the CD45RA − fractions but this did not reach statistical significance (Supplementary Figure S4f) .
Efficacy of clinical-grade CD62L depletion and cellular composition Using steady-state leukapheresis products from allogeneic sibling donors, three clinical-scale runs for validation of CD62L depletion were performed under GMP conditions. All CD62L-depleted fractions tested negative for bacterial and fungal growth using aerobic and anaerobic blood culture bottles following 10-day incubation, and environmental monitoring and airborne particle counting were within the permitted range for current GMP. As shown in Table 1 , the median viable total nucleated cell count preprocessing was 911 × 10 6 (581-1316) with viability of 490% by TO-PRO-3-Iodide staining. Processing time was~2.5 h with a median viability of 90% in CD62L-depleted fractions. The median viable total nucleated cell count in CD62L-depleted fractions was 286.2 × 10 6 (109-507; Functions of T cells within the CD62L-depleted product CD62L-depleted and unmanipulated leukapheresis products were analysed for pathogen-specific responses by direct in vitro (Figure 3a) . As shown in Figures 3b and c, reactivity to both EBV and CMV was maintained in CD62L-depleted fractions. The alloreactivity of CD62L-depleted fractions following clinicalscale runs was measured using a HLA-mismatched MLR and compared with unmodified cells, with proliferation in relation to autologous controls determined after a 5-day culture by CFSE dilution. Cumulative data from three clinical-scale CD62L depletions (Figure 3d) showed reduced T-cell alloreactivity of CD62L-depleted cells compared with unmanipulated leukapheresis products at each stimulator-responder ratio.
DISCUSSION
In this study, we have demonstrated the feasibility of T N depletion from donor leukapheresis collections in full-scale runs using clinical-grade CD62L immunomagnetic beads under GMP conditions. We observed a median 2.9 log reduction in CD62L + cells and the CD62L − fraction retained antiviral immunity whereas alloreactivity to HLA-mismatched stimulators was reduced.
The depletion of cells with low-level expression of CD62L is likely to explain the CD3 + CD62L − T cell yield of 43%; comparable cell yields were observed following CD45RA depletion. 7 The enrichment of anti-CMV and anti-EBV responses was modest (mean 2.0-and 2.7-fold, respectively) and we therefore anticipate that starting doses of CD62L − DLI in clinical trials will be similar to those used in studies of unmanipulated DLI, that is, in the range of 3 × 10 5 -1 × 10 6 /kg recipient wt. 12 Whereas sufficient cells for clinical use can readily be obtained from a leukapheresis product, we estimate that~2 units of peripheral blood would need to be drawn to obtain a dose of 1 × 10 6 CD3 cells/kg recipient wt making this an unsuitable starting product.
In contrast to T N depletion using CD45RA immunomagentic beads, CD62L depletion led to a moderate increase, rather than a decrease, in total CD8 + T cells so that the final ratio to CD4 + T cells was inverted. This disparity relates to the retention of the CD45RA + CD8 + T EMRA population that is removed in CD45RA − products. 7, 8 Although T EMRA are terminally differentiated cells, they rapidly produce effector cytokines and possess high cytolytic potential 13 and it is possible that such cells will be important in establishing early immunity to pathogens following allo-SCT. According to the linear model of differentiation, the CD8 + T EMRA population can also differentiate from CD45RA − T EM or CD45RA − CD62L + central memory T cells (T CM ), 14 both of which are contained within a CD45RA − product. Because T CM are highly effective at reconstituting virus-specific immunity, 15 it is possible that their retention in CD45RA − products will offset the effects of an overall reduction in CD8 + T-cell numbers. Furthermore, it also possible that the higher content of CD4 + T cells in the CD45RA − product will be better at providing antiviral responses that are − and CD62L + cells in a CFSE proliferation assay at three different stimulator:responder ratios.
primarily CD4 + T-cell mediated; in this regard we have observed that CD4 + T-cell responses to adenovirus were maintained in the fraction depleted of CD62L-expressing cells (Supplementary Figure S5) . Of note, both CD62L-and CD45RA − -depleted products will lack putative memory stem cells that possess a CD45RA + CD62L + CD95 + phenotype and have been proposed to be important in maintaining responses to viral Ags. 16 Thus, it will be of interest in clinical trials to determine how the kinetics and sustainability of CD8 + T-cell immune reconstitution are affected by the total N and memory subset of T cells transferred.
The key clinical question is whether CD62L-or CD45RA-depleted products will reduce the risk of GvHD. One potentially relevant difference between the CD62L-and CD45RA-depletion methods is the greater removal of T CM in the former setting. Human T CM that have been pre-activated in vitro with cytokines and anti-CD28 induce very severe xenogenic-GvHD, 17 as do murine T CM that have been primed against alloantigen. 5 Because the human T-cell repertoire may contain Ag-experienced T CM with direct (for example, anti-HY) 18 or cross-reactivity (for example, antiviral) 19 with alloantigen, it is a potential risk that pre-sensitised T CM will increase the risk of GvHD. Because neither in vitro assays nor pre-clinical data fully represent the clinical setting, the issue of whether CD62L-or CD45RA-depleted products are more likely to induce GVHD will therefore require testing formally in clinical trials.
In this study, we performed CD62L depletion of steady-state leukapheresis products rather than mobilised grafts. A disadvantage of the CD62L-depletion method is that both G-CSF mobilisation and cryopreservation induce shedding of CD62L, 20, 21 thus increasing the risk that removal of T N will be incomplete. In both cases, CD62L expression returns to baseline following incubation of cells for 18 h at 37°C (data not shown); however, the additional culture step constitutes a significant manipulation and thus, the product would be subject to regulation as an ATMP. However, recent data indicates that grafts mobilized with Plerixafor alone do not downregulate CD62L and in this case, CD62L depletion could theoretically be used. 20 In addition, unlike G-CSF, Plerixafor does not alter the cytokine or effector profile of T cells toward a Th2 phenotype and there may therefore be some advantages for this approach especially where rapid restoration of immunity to intracellular pathogens via memory-type Th1 responses is required.
CE certification of the CliniMACS CD62L reagent is currently under consideration in the EU and it is anticipated that it will be commercially available in the near future. The advantages of CD62L-or CD45RA-depletion strategies are that they could be applied readily at relatively low cost by most transplant centres and do not require regulation as an ATMP. In contrast, other methods for allodepletion, for example, targeting cell-surface activation markers following in vitro stimulation 1 or transfer of suicide genes, require complex and costly manufacturing processes that would be limited to those sites holding the requisite ATMP manufacturing licences. A potential disadvantage of memory selection is that Ag specificity is not defined, as for example, in strategies employed to enrich for virus-or tumourspecific T cells from the donor or to re-direct specificity through gene transfer of chimeric Ag or TCRs. Indeed, recent studies have suggested that removal of naive T cells could potentially compromise the development of anti-tumour immunity. 11, [22] [23] [24] [25] Furthermore, there are no methods to eliminate transferred cells, should severe GVHD occur and thus, safety and efficacy testing in the context of clinical trials will be essential before this method can be deployed.
